HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Serotonin syndrome probably triggered by a morphine-phenelzine interaction.

Abstract
Serotonin syndrome is a potentially life-threatening condition caused by excessive central and peripheral stimulation of serotonin brainstem receptors, usually triggered by inadvertent interactions between agents with serotonergic activity. Evidence supporting an association between nonserotonergic opiates, such as oxycodone or morphine, and serotonin syndrome is very limited and even contradictory. In this case report, we describe a patient who developed serotonergic-adverse effects likely precipitated by an interaction between morphine and phenelzine. A 57-year-old woman presented to the emergency department with complaints of increasing visual hallucinations, restlessness, photophobia, dizziness, neck stiffness, occipital headache, confusion, sweating, tachycardia, and nausea over the previous week. On admission, her blood pressure was 185/65 mm Hg, and clonus was noted in the lower extremities. The patient was hospitalized 10 days earlier for cellulitis of the left breast secondary to a left mastectomy 5 months earlier, and a short course of oral morphine was prescribed for pain control. Her routine medications consisted of aspirin, atorvastatin, bisoprolol, clopidogrel, gabapentin, omeprazole, phenelzine, and ramipril. Supportive measures were initiated on admission. Phenelzine and morphine were discontinued immediately, leading to a progressive resolution of symptoms over the next 48 hours. Phenelzine was restarted on discharge without further complications. Use of the Drug Interaction Probability Scale indicated a probable relationship (score of 6) between the patient's development of serotonin syndrome and the combination of morphine and phenelzine. The mechanism underlying this interaction, however, remains unclear and warrants further investigation. Clinicians should carefully weigh the risk and benefits of initiating morphine in patients taking monoamine oxidase inhibitors or any other serotonin-enhancing drugs.
AuthorsHector Mateo-Carrasco, Eva María Muñoz-Aguilera, Juan Manuel García-Torrecillas, Hiba Abu Al-Robb
JournalPharmacotherapy (Pharmacotherapy) Vol. 35 Issue 6 Pg. e102-5 (Jun 2015) ISSN: 1875-9114 [Electronic] United States
PMID25903219 (Publication Type: Case Reports, Journal Article)
Copyright© 2015 Pharmacotherapy Publications, Inc.
Chemical References
  • Analgesics, Opioid
  • Monoamine Oxidase Inhibitors
  • Morphine
  • Phenelzine
Topics
  • Analgesics, Opioid (adverse effects)
  • Drug Interactions
  • Female
  • Humans
  • Middle Aged
  • Monoamine Oxidase Inhibitors (adverse effects)
  • Morphine (adverse effects)
  • Phenelzine (adverse effects)
  • Serotonin Syndrome (chemically induced)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: